KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Expenses: 2012-2025

Historic Operating Expenses for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to $1.0 billion.

  • Sarepta Therapeutics' Operating Expenses rose 187.44% to $1.0 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $2.6 billion, marking a year-over-year increase of 76.34%. This contributed to the annual value of $1.7 billion for FY2024, which is 11.43% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Operating Expenses of $1.0 billion as of Q2 2025, which was up 74.21% from $600.0 million recorded in Q1 2025.
  • In the past 5 years, Sarepta Therapeutics' Operating Expenses ranged from a high of $1.0 billion in Q2 2025 and a low of $223.9 million during Q3 2021.
  • Its 3-year average for Operating Expenses is $484.0 million, with a median of $393.2 million in 2023.
  • Per our database at Business Quant, Sarepta Therapeutics' Operating Expenses dropped by 20.33% in 2021 and then spiked by 187.44% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Operating Expenses stood at $307.3 million in 2021, then increased by 18.87% to $365.3 million in 2022, then rose by 1.89% to $372.2 million in 2023, then spiked by 33.47% to $496.7 million in 2024, then surged by 187.44% to $1.0 billion in 2025.
  • Its Operating Expenses stands at $1.0 billion for Q2 2025, versus $600.0 million for Q1 2025 and $496.7 million for Q4 2024.